Natco Pharma Reports Stable Financial Performance with Improved Sales and Liquidity in August 2025

Natco Pharma, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently released its financial results for the quarter ending June 2025. The report, published on August 12, 2025, indicates a stable financial performance during this period. Notably, the company's score has undergone an adjustment, rising to 3 from 1 over the last three months.
The financial data reveals that Natco Pharma's net sales for the quarter reached Rs 1,328.90 crore, reflecting a growth of 20.0% compared to the average net sales of Rs 1,107.38 crore from the previous four quarters. This positive trend in sales suggests a favorable near-term outlook for the company.

Additionally, the company's cash and cash equivalents have reached their highest level in the last six half-yearly periods, totaling Rs 2,176.00 crore, indicating an enhancement in short-term liquidity. Furthermore, the debtors turnover ratio has also shown improvement, recorded at 3.55 times, the highest in the last five half-yearly periods, suggesting that Natco Pharma has been effective in settling its debtors more swiftly.

For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.